Home  »  Finance   »  Vascular Biogenics Ltd. (NASDAQ: VBLT) – Ana...

Vascular Biogenics Ltd. (NASDAQ: VBLT) – Analysts’ Revisions Point To Positive Sentiment

Vascular Biogenics Ltd. (NASDAQ:VBLT) traded at $0.16 at last check on Wednesday, November 23, made an upward move of 12.92% on its previous day’s price.

Looking at the stock we see that its previous close was $0.14 and the beta (5Y monthly) reads 0.69 with the day’s price range being $0.1302 – $0.1425. In terms of its 52-week price range, VBLT has a high of $2.38 and a low of $0.11. The company’s stock has gained about 5.64% over that past 30 days.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

Vascular Biogenics Ltd. has a market cap of $9.73 million and is expected to release its quarterly earnings report on Nov 14, 2022 – Nov 18, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.11, with the EPS growth for the year raised at -$0.45 for 2022 and -$0.34 for next year.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $200k, with a low of $200k and a high of $200k. The median projection represents growth squeezing down to 0.50% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $500k, or -34.90% down from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the VBLT stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the Vascular Biogenics Ltd. (VBLT) stock as a Hold, while 0 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 20.66% off its SMA20 and 7.54% from its 50-day simple moving average. The RSI (14) is pointing at 63.32 while the volatility over the past week is 8.98% and jumps to 10.37% over the past one month. The beta value is 0.62, while the average true range (ATR) is currently pointing at 0.01. The average price target for the stock over the next 12 months is $5.00, with the estimates having a low of $5.00 and a high of $5.00. These price ends are -3025.0% and -3025.0% off the today’s price level respectively, although investors could be excited at the prospect of a -3025.0% if the VBLT share price touches on the median price of $5.00.

Let’s briefly compare Vascular Biogenics Ltd. (VBLT) stock to its peers. We find that today’s price change of 12.92% and -93.37% over the past 12 months for VBLT competes that of Merrimack Pharmaceuticals Inc. (MACK), which has seen its stock price fall -0.95% in the latest trading session and is 188.84% over the last one year. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.51% and 0.24%, respectively, in early deals.

Coming back to Vascular Biogenics Ltd. (NASDAQ:VBLT), we note that the average 3-month trading volume was 1.47 million, while that of the preceding 10-day period stands at 0.99 million. Current shares outstanding are 77.40 million.

The insiders hold 22.48% of the company’s shares while institutions hold 17.10%. The data shows that short shares as of Oct 13, 2022, stood at 0.16 million at a short ratio of 0.1. This represents a 0.23% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 0.1 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -92.97% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]